Biosyent's total assets for Q3 2024 were C$45.47M, an increase of 9.63% from the previous quarter. TSE:RX total liabilities were C$8.12M for the fiscal quarter, a 34.06% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.